DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,890,643 | +12.1% | 39,866 | +8.4% | 1.38% | +16.9% |
Q2 2023 | $8,823,972 | +0.8% | 36,767 | +5.9% | 1.18% | -3.7% |
Q1 2023 | $8,750,211 | -12.6% | 34,718 | -8.0% | 1.22% | -16.3% |
Q4 2022 | $10,013,646 | +7.0% | 37,728 | +4.2% | 1.46% | -5.3% |
Q3 2022 | $9,355,000 | -0.1% | 36,219 | -2.0% | 1.54% | +7.6% |
Q2 2022 | $9,367,000 | -16.3% | 36,949 | -3.2% | 1.43% | -1.6% |
Q1 2022 | $11,195,000 | -16.5% | 38,163 | -6.4% | 1.45% | -13.3% |
Q4 2021 | $13,415,000 | +7.8% | 40,773 | -0.3% | 1.68% | -1.5% |
Q3 2021 | $12,445,000 | +12.5% | 40,878 | -0.9% | 1.70% | +16.2% |
Q2 2021 | $11,067,000 | +28.4% | 41,238 | +7.7% | 1.46% | +18.3% |
Q1 2021 | $8,620,000 | -0.4% | 38,298 | -1.7% | 1.24% | -6.1% |
Q4 2020 | $8,652,000 | -6.9% | 38,948 | -9.8% | 1.32% | -18.8% |
Q3 2020 | $9,298,000 | +18.1% | 43,182 | -3.0% | 1.62% | +6.6% |
Q2 2020 | $7,873,000 | +45.4% | 44,520 | +13.8% | 1.52% | +13.6% |
Q1 2020 | $5,413,000 | +17.2% | 39,111 | +30.0% | 1.34% | +27.2% |
Q4 2019 | $4,617,000 | +74.4% | 30,081 | +64.1% | 1.05% | +45.4% |
Q3 2019 | $2,648,000 | – | 18,331 | – | 0.72% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
Third Point | 2,450,000 | $607,845,000 | 9.22% |
Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |